Considering our findings with those of previous studies with [11C]MET and [18F]FET PET [6,7,8], in which higher values of uptake of the radiopharmaceutical in IDH wild-type gliomas compared to IDH mutant gliomas were demonstrated, we support the hypothesis of different behavior of the IDH status of glioma on amino acid tracers metabolism and in particular a lack of influence only on [18F]FDOPA uptake. This evidence concerns the gene IDH1 and central nervous system cancer.